Opto-Acoustic Nomograms for Improving Breast Cancer Diagnosis

San Antonio Breast Cancer Symposium, San Antonio, Texas, December 9 – 13, 2014

Philip Lavin PhD¹ and A. Thomas Stavros MD²


Boston Biostatistics Research Foundation, Framingham, MA1, Seno Medical Instruments, Inc., San Antonio, TX2

BACKGROUND

Imagio® (Seno Medical Instruments, Inc.) is currently an investigational medical device being tested in a Pivotal Study for FDA approval. Imagio is a fusion of dual wavelength laser opto-acoustics co-registered with B-mode gray scale ultrasound and shows both structural and functional imaging information about potentially suspicious breast masses without the need for administering contrast agents, radionuclides, or exposing patients to x-irradiation. This hybrid imaging technology has been previously introduced in presentations at medical conferences (1, 2, 3). It may have the ability to increase both sensitivity and specificity of sonographically evident breast masses (1, 2, 3).

OBJECTIVES


Diagnostic specificity remains disappointingly low for breast imaging modalities that are optimized to achieve near 100% sensitivity. Opto-acoustic (OA) imaging is a fusion of real time co-registered, interleaved OA and gray scale information that shows both functional findings (relative de-oxygenation of hemoglobin) and morphologic data (tumor angiogenesis) within and around breast masses using a hand-held duplex OA probe. We assess the improvement in sensitivities and specificities achieved with nomograms (N) based upon regression models that simultaneously classify (CL) benign (B) vs. malignant (M) and also project probability of malignancy (POM) based on five semi-quantitative OA features that were scored by 23 independent readers (IRs) and an expert reader (ER). We examined both OA individual feature scoring alone and OA feature scoring aided by nomograms for their performances in distinguishing between benign and malignant breast masses.




METHODS

102 masses from a series of 100 subjects with 80 biopsies (42 B, 38 M) were blindly evaluated and their features scored by 23 independent readers and one expert reader prior to core biopsy in 80 subjects, (22 masses considered BI-RADS 3 were not biopsied.) Three internal OA findings (density of vascularity [V], relative blood oxygen saturation [O], and hemoglobin [H]) and two external OA findings (boundary zone [Z] and peri-tumoral radiating vessels [R]) were assigned 0-5/6 ordinal scores. Feature distributions were compared using a two-sided, Kruskal-Wallis test for benign vs. malignant masses and for benign vs. not biopsied masses.


Separate nomograms were constructed using a logistic regression model for the probability of malignancy (CL) and using a linear regression model with an arc sine transformation (POM); both models only used the ordinal feature scores. The coefficients for each model were based on the outcomes of the expert reader (ER). For each mass read, the predicted outcomes were generated. The predicted outcomes were evaluated using an averaged 10% threshold, which was pre-defined.



This 1.1 cm grade 3 invasive duct carcinoma shows an intense red (de-oxygenated) blush correlations show that diffuse blushes such as this to correspond to innumerable tightly clustered small tumor vessels that are too small to resolve individually.



This tiny (maximum diameter = 3.4 mm) grade 1 invasive duct carcinoma has red (de-oxygenated) tumor vessels on its surface and extending into the surrounding tissues, but relatively little demonstrable tumor vascularity in its central nidus.



This 0.9 cm fibroadenoma is devoid of internal tumor vascularity and internal de-oxygenation. It only slightly indents a prominent, but normal, breast vein that passes directly anterior to the fibroadenoama.

RESULTS

There were consistent significant differences between the feature distributions for benign vs. malignant: density of vascularity (17/23 IRs), relative blood oxygen saturation (11/23 IRs), hemoglobin (17/23 IRs), capsular boundary zone (all IRs), and peri-tumoral radiating vessels (all IRs) always with lower scores for benign vs.

Differences were minimal for benign vs. not biopsied: density of vascularity (17/23 IRs), relative blood oxygen saturation (11/23 IRs), hemoglobin (17/23 IRs), capsular boundary zone (all IRs), and peri-tumoral radiating vessels (all IRs) always with lower scores for benign vs. malignant.

	FEATURE COMPARISONS (23 READERS)							
			Vessels	Blush	Hemoglobin	Capsular BZ	Ext PRV	
	Benign vs. Malignant	% p<0.05	17/23	11/23	17/23	23/23	23/23	
		KW P- value	All highly significant: p<0.000001					
	Benign vs. Not Biopsied	% p<0.05	0/23	0/23	1/23	0/23	2/23	
		KW P- value	P=0.13	P=0.29	P=0.028	P=0.007	P=0.0014	
	Masses not biopsied being re-evaluated after 12 months					months		

The mean IR sensitivity across all 23 readers was 97.6% and was 97.2% for the expert reader.

The mean IR specificity across all 23 readers was 38.2% and was 71.8% for the expert reader.

The mean specificities from the nomograms were 49% (POM), 43% (CL), and 47.2% (averaged) across all 23 readers.

This represents a 9% absolute increase in the specificity across all 23 readers.

Seno PIONEER Pilot OA Specificity Enhancement Using Averaged Prediction Models

	Obse	erved	10% Threshold		
Reader	Sensitivity	Specificity	Sensitivity	Specificity	
All 23	97.6%	38.2%	91.1%	47.2%	
Expert	97.2%	71.8%	94.4%	66.7%	
Pooled	97.6%	39.6%	93.3%	48.1%	

9.2% Absolute Gain in Specificity for Pre-defined Averaged 10% Prediction Threshold

CONCLUSION

The study results indicate that:

- OA findings to differentiate between benign and malignant masses can be independently and quickly mastered by practicing IRs to consistently differentiate between benign and malignant breast masses.
- Nomograms may offer further confidence to enhance decision making to improve specificity by helping readers use the individual features scores together more effectively.

If confirmed in the Pivotal Study, OA findings may be useful in differentiation and thus sparing biopsies in addition to performing more customized surgeries.

REFERENCES

- 1. Opto-acoustic Breast Imaging: A Novel Fusion of Functional and Morphologic Imaging. Reni S. Butler, MD, A. Thomas Stavros, MD, F. Lee Tucker, MD, Michael J. Ulissey, MD. Radiological Society of North America. Presentation December 2013.
- 2. Opto-acoustic Imaging in the Evaluation of BI-RADS 3 Lesions: Finding and Implications. A. T. Stavros, MD, A. Lerner, MD, F. Lee Tucker, MD, B. Boyd, RN, R. Fine, MD, W. Burak, MD. National Consortium of Breast Centers. Presentation March 2014.
- 3. Breast Mass Classification Based on Opto-acoustic Features Using Data Mining. Philip Lavin, PhD, Michael J. Ulissey, MD, David Schoenfeld, PhD, and A. Thomas Stavros, MD. American Institute for Ultrasound in Medicine. Presentation April 2014.



